8-K: Aquestive Advances Anaphylm, Reports Q2 Loss

Aquestive Therapeutics announced FDA acceptance of its Anaphylm NDA with a January 2026 PDUFA date, alongside a Q2 2025 net loss of $13.5 million and global expansion plans.

Summary

• The FDA accepted the New Drug Application (NDA) submission for Anaphylm (epinephrine) Sublingual Film, setting a PDUFA date for January 31, 2026.
• Preparations are ongoing for a potential U.S. launch of Anaphylm in Q1 2026, if approved by the FDA.
• The company is accelerating Anaphylm's global expansion strategy, with initial regulatory engagements underway in Canada (meeting in September 2025) and the European Union (initial briefing book submitted).
• Work continues towards an anticipated Investigational New Drug (IND) Application submission for AQST-108 (epinephrine) Topical Gel for the treatment of alopecia areata in Q4 2025.
• Libervant (diazepam) Buccal Film's regulatory status was revised from full to tentative approval due to a court decision related to orphan drug exclusivity, with a relaunch targeted for 2027 or sooner if full marketing approval is granted.
• Total revenues for Q2 2025 were $10.0 million, a decrease from $20.1 million in Q2 2024 (which included a one-time recognition of deferred revenue). Excluding this one-time impact, revenues increased by $0.3 million, or 3% year-over-year.
• Manufacture and supply revenue increased to $9.6 million in Q2 2025 from $8.1 million in Q2 2024, primarily driven by Ondif revenues, partially offset by decreases in Suboxone revenues.
• Net loss for Q2 2025 was $13.5 million, or $0.14 per basic and diluted share, compared to a net loss of $2.7 million, or $0.03 per share, in Q2 2024. Excluding the one-time deferred revenue, the Q2 2024 net loss was $13.2 million.
• Non-GAAP adjusted EBITDA loss was $9.3 million in Q2 2025, compared to non-GAAP adjusted EBITDA income of $1.8 million in Q2 2024. Excluding the one-time deferred revenue, Q2 2024 non-GAAP adjusted EBITDA was a loss of $8.6 million.
• Cash and cash equivalents stood at $60.5 million as of June 30, 2025.
• Full-year 2025 financial guidance includes total revenues of $44 million to $50 million and a non-GAAP adjusted EBITDA loss of $47 million to $51 million.
• Anaphylm pediatric study results demonstrated comparable pharmacokinetic (PK) curves in adult and pediatric subjects and a similar pharmacodynamic (PD) response.

Sentiment

Score: 6

Explanation: While the company made significant regulatory progress with Anaphylm and is advancing other pipeline assets, the increased net loss and negative adjusted EBITDA, coupled with the delay for Libervant, temper the overall sentiment. The cash runway into 2026 is positive, but the need for future financing is acknowledged as a risk.

Positives

• The FDA accepted the NDA submission for Anaphylm, initiating its review process and setting a PDUFA date of January 31, 2026.
• Preparations for a Q1 2026 U.S. launch of Anaphylm are underway, including building a commercial launch team and leveraging existing infrastructure.
• The company is accelerating Anaphylm's global expansion strategy with initial regulatory engagements planned in Canada and the European Union.
• Anaphylm pediatric study results showed comparable PK curves in adult and pediatric subjects and a similar pharmacodynamic response, supporting its broad applicability.
• AQST-108 (epinephrine) Topical Gel is advancing towards an IND submission in Q4 2025 for alopecia areata, a condition with a significant market opportunity (over $1 billion for existing systemic treatments).
• The manufacturing business remains steady, with growth in newer collaborations (e.g., Ondif) partially offsetting the gradual decline of Suboxone.
• The company's supply chain is largely unaffected by tariffs, providing continued reliability and stability in production and global distribution.
• A strong balance sheet with projected cash and cash equivalents of $60.5 million as of June 30, 2025, provides a cash runway into 2026.

Negatives

• Net loss for Q2 2025 increased to $13.5 million, compared to a net loss of $2.7 million in Q2 2024 (or $13.2 million excluding one-time deferred revenue), indicating a worsening financial performance.
• Total revenues decreased to $10.0 million in Q2 2025 from $20.1 million in Q2 2024, primarily due to the absence of a one-time recognition of deferred revenue in the prior year.
• Non-GAAP adjusted EBITDA shifted to a loss of $9.3 million in Q2 2025, from an income of $1.8 million in Q2 2024 (or a loss of $8.6 million excluding one-time deferred revenue).
• Selling, general and administrative expenses increased to $12.7 million in Q2 2025 from $11.4 million in Q2 2024, driven by higher commercial spending, regulatory fees, and personnel costs.
• Libervant's regulatory status was revised from full to tentative approval, delaying its relaunch until 2027 or sooner, due to a court decision related to orphan drug exclusivity of another drug product.
• Eroding market share for Suboxone Sublingual Film continues, which accounts for a substantial part of current operating revenue.

Risks

• Risks associated with development work, including delays or changes to the timing, cost, and success of product development activities and clinical trials for Anaphylm, AQST-108, and other product candidates.
• Risk of delays in advancement of the regulatory approval process through the FDA for product candidates, including Anaphylm and AQST-108, or failure to receive FDA approval at all.
• Risk of the company's ability to generate sufficient clinical data for approval of product candidates, including with respect to pharmacokinetic and pharmacodynamic (PK/PD) comparability submission for FDA approval of Anaphylm.
• Risks associated with the ability to address the FDA's comments on the NDA, including the risk that the FDA may require additional clinical studies for approval of Anaphylm.
• Risks associated with the success of any competing products, including generics.
• Risks and uncertainties inherent in commercializing a new product (including technology risks, financial risks, market risks, implementation risks, and regulatory limitations).
• Risk of development of a sales and marketing capability for commercialization of product candidates, including Anaphylm, Libervant, and AQST-108.
• Risks associated with the potential impact on the value of the company of the sale or outlicensing of products and product candidates.
• Risk of insufficient capital and cash resources, including insufficient access to available debt and equity financing (including under the ATM facility) and revenues from operations, to satisfy all short-term and longer-term liquidity and cash requirements and other cash needs, including to commence principal payments on 13.5% Notes in 2026, and to fund future clinical development and commercial activities.
• Risk that manufacturing capabilities will be insufficient to support demand of product candidates in the U.S. and abroad, if approved, and licensed products.
• Risk of eroding market share for Suboxone as a sunsetting product, which accounts for a substantial part of current operating revenue.
• Risk of default of debt instruments.
• Risks related to the outsourcing of certain sales, marketing, and other operational and staff functions to third parties.
• Risk of the rate and degree of market acceptance in the U.S. and abroad of Libervant, Anaphylm, AQST-108, and other product candidates, if approved, and for licensed products.
• Risks associated with compliance with all FDA and other governmental and customer requirements for manufacturing facilities.
• Risks associated with intellectual property rights and infringement claims relating to products, including timely issuance of patent applications.
• Risk of legislation and regulatory actions and changes in laws or regulations affecting the business, including relating to product pricing, reimbursement, or access.
• Risk of loss of significant customers.
• Risks related to claims and legal proceedings against the company, including patent infringement, securities, business torts, investigative, product safety or efficacy, and antitrust litigation matters.
• Risk of product recalls and withdrawals.
• Risks related to any disruptions in information technology networks and systems, including the impact of cybersecurity attacks and increased cybersecurity attacks due to remote working arrangements.
• Risk of adverse developments affecting the financial services industry, inflation, and changing interest rates.
• Risks related to the impact of other pandemic diseases on the business.
• Risks and uncertainties related to general economic, political (including the Ukraine and Israel wars and other acts of war and terrorism), business, industry, regulatory, financial, and market conditions and other unusual items.
• Risks related to uncertainty about presidential administration initiatives and their impact on the business, including imposition of tariffs and other trade restrictions.

Future Outlook

The company projects full-year 2025 total revenues between $44 million and $50 million, with a non-GAAP adjusted EBITDA loss expected to be between $47 million and $51 million. Key product milestones include a PDUFA date for Anaphylm on January 31, 2026, with a planned U.S. launch in Q1 2026 if approved, and an anticipated IND submission for AQST-108 in Q4 2025. Libervant's relaunch is targeted for 2027 or sooner.

Management Comments

• "The second quarter marked a pivotal step forward for our Company with the FDA's acceptance of our NDA for Anaphylm which, if approved by the FDA, will be the first and only oral, sublingual film epinephrine product."
• "As we advance preparations for a potential U.S. launch in 2026, we are also laying the groundwork for global expansion with initial regulatory engagements now underway with Canada and the EU."
• "I'm proud of our momentum and confident in our ability to bring forward a solution that makes epinephrine emergency treatment more accessible, portable, and patient-friendly."
• The company continues to believe that limiting access to a differentiated, non-invasive formulation (Libervant) restricts patient choice and imposes an unnecessary burden on caregivers.

Industry Context

The company is positioning Anaphylm to address significant unmet needs in the anaphylaxis market, which is projected to grow to $2 billion by 2031, by offering a needle-free, orally administered alternative to existing auto-injectors. This aligns with increasing patient awareness and demand for more convenient solutions. For AQST-108, the company aims to enter the alopecia areata market, currently dominated by systemic JAK inhibitors with known side effects and black box warnings, by offering a topical treatment that could capture meaningful market share and potentially improve treatment outcomes.

Comparison to Industry Standards

• Anaphylm's pharmacokinetic profile is comparable to leading epinephrine injectables, offering a non-invasive, orally administered alternative that could improve carry rates and simplify emergency response.
• Anaphylm consistently delivers a median T-max of 12 minutes and achieves therapeutic blood concentrations in as little as 5 minutes, which is critical for rapid-onset anaphylaxis, differentiating it from existing device-based therapies.
• AQST-108 is uniquely positioned as a potential topical treatment for alopecia areata, contrasting with existing systemic JAK inhibitors (e.g., Olumiant, Litfulo) that carry 'black box' warnings and systemic side effects.
• The current estimated market for JAK inhibitors in alopecia areata is over $1 billion, indicating a substantial opportunity for a differentiated topical product like AQST-108 that may not cause systemic side effects.
• Patient and healthcare professional (HCP) surveys indicate high interest (80% prefer non-injection, 95% interested in film-dosing) in alternatives to existing device-based epinephrine therapies like EpiPen, which are often not carried due to bulkiness, fear of needles, and social stigma.

Stakeholder Impact

• Shareholders face potential for significant value creation if Anaphylm is approved and successfully launched, but also risks from increased losses, potential future capital raises, and Libervant delays.
• Patients with severe allergic reactions (anaphylaxis) could benefit from a novel, needle-free, and more accessible epinephrine treatment (Anaphylm) to improve emergency response and carry rates.
• Patients with alopecia areata may gain a new topical treatment option (AQST-108) that could potentially avoid systemic side effects associated with current therapies.
• Epilepsy patients and their caregivers continue to face delays in accessing Libervant due to regulatory issues, limiting choice for a differentiated, non-invasive formulation.
• Employees are impacted by the ongoing efforts to build commercial launch teams for Anaphylm and the diversification of manufacturing operations.
• Customers and partners in manufacturing collaborations benefit from stable operations, but those tied to Suboxone may see continued revenue decline.

Next Steps

• Prepare for a possible Advisory Committee meeting with the FDA for Anaphylm.
• Continue U.S. commercial readiness strategy for Anaphylm, including building a launch team and engaging with healthcare professionals, payers, and advocacy groups.
• Conduct initial regulatory meetings in Canada and the European Union for Anaphylm.
• Submit an Investigational New Drug Application (IND) for AQST-108 for alopecia areata in Q4 2025.
• Host a conference call on August 12, 2025, to discuss Q2 2025 results.
• Relaunch Libervant in 2027 or sooner if full marketing approval is granted by the FDA.
• Commence Phase 2a study for AQST-108 in Q2 2026.
• Commence Phase 2b study for AQST-108 in Q3 2026.

Key Dates

Recommendation

The FDA's acceptance of the Anaphylm NDA and the setting of a PDUFA date are significant positive catalysts, indicating clear progress towards a potentially transformative product. The global expansion strategy for Anaphylm and the advancement of AQST-108 also add long-term value. However, the increased net loss and negative adjusted EBITDA in Q2 2025, coupled with the continued delay for Libervant, introduce near-term financial headwinds and regulatory uncertainty. The company's cash runway into 2026 is positive, but the explicit mention of potential capital raise risks suggests future dilution. Given the mix of strong pipeline progress and financial challenges, a 'hold' recommendation is appropriate, awaiting further clarity on Anaphylm's approval and commercialization, as well as improved financial performance.

Keywords

Aquestive Therapeutics, AQST, Anaphylm, epinephrine, sublingual film, anaphylaxis, FDA NDA, PDUFA, AQST-108, topical gel, alopecia areata, Libervant, diazepam, buccal film, seizure clusters, pharmaceuticals, drug development, PharmFilm, AdrenaVerse, financial results, Q2 2025, biotechnology, specialty pharma